Citations

Clear

240 citation(s) found for "Miller, Virginia".

C27-18 Post Lung Transplantation Fungal Infections: A Multicenter Real-World Analysis (2005-2024)
Wahab, A, Parmar, K, Vissichelli, N, Miller, K, Brath, L, Pennington, K, Wahab, Abdul, Vissichelli, Nicole C.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.6611 Get It

Abstract Rationale Fungal infections remain a major cause of morbidity and mortality post lung transplant due to unique exposure of the allograft to the external environment and the intensity of immunosuppression. Single-center studies have described variable rates of fungal infections. Contemporary population-level data with temporal trends, pathogen distribution, and associated outcomes are limited. Leveraging a large multicenter real-world dataset, we aimed to characterize incidence, prevalence and clinical outcomes of fungal infections among adult lung-transplant recipients. Methods Data were obtained from the TriNetX Global Collaborative Network (160 HCOs). Adult lung-transplant recipients (≥18 years) were identified between 2005 and 2024, using ICD and CPT procedure codes. Patients with solid organ transplants other than lung, combined-organ transplant or stem-cell transplant and HIV patients were excluded. Patients with pre transplant fungal infections were also excluded. Pre-transplant characteristics included demographics, comorbidities within a year, laboratory values within seven days, and medication within 90 days before transplantation. Post-transplant fungal infections were identified using ICD-10 codes for Aspergillus, Candida, Cryptococcus, Mucorales, Histoplasma, Blastomyces, Coccidioides, and Pneumocystis. TriNetX platform was utilized for statistical analysis. Incidence and prevalence of infections, all-cause mortality and transplant rejection were analyzed. Results A total of 12,857 adult lung-transplant recipients were identified. The mean age at transplantation was 57.6 ± 13.4 years, with a male predominance of (57%) and majority were white (65%). Average BMI was 26.8 ± 5.7 kg/m². The most common pulmonary conditions were COPD (15%), pulmonary fibrosis (17%), pulmonary hypertension (9%), bronchiectasis (3%), and cystic fibrosis (3%). Pre-transplant fungal and viral screening assays were rarely available (<1%). Medication exposure within 90 days prior to transplant demonstrated prednisone prescription (17%) methylprednisolone (7%), tacrolimus (6%), and mycophenolate mofetil (7%). Azathioprine and basiliximab were used in 2% each. Systemic antifungals (voriconazole, posaconazole, or fluconazole) in approximately 1% each.The overall incidence of post-transplant fungal infection was 3 % across full study period, rising to 7% in the modern era (2015-2024). Most frequently identified pathogens were Candida spp. (4.8%) and Aspergillus spp. (2.9%), followed by Pneumocystis Jirovecii (0.5%). Infection rates increased from 22 per 1,000 (2005-2014) to 75 per 1,000 (2015-2024) suggestive of improved diagnostic sensitivity and data capture, and longer post-transplant survival. All-cause mortality 5-year post transplant was 22.1%, and rejection rate was 22.5%. Conclusion Our study highlights a rising burden of fungal infections among lung-transplant recipients with potential implications for early post-transplant surveillance and antifungal prophylaxis strategies. This abstract is funded by: None
C27-17 Impact of Post-Transplant Fungal Infection on Mortality and Graft Outcomes in Lung Transplant Recipients: A Multicenter Propensity-Matched Analysis
Wahab, A, Parmar, K, Vissichelli, N, Miller, K, Brath, L, Pennington, K, Wahab, Abdul, Vissichelli, Nicole C.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.6610 Get It

Abstract Rationale Fungal infections are common after lung transplantation and may adversely affect graft function and survival, but long-term outcomes remain incompletely defined. Using a large multicenter real-world dataset, we aimed to study the impact of post-transplant fungal infections on clinical outcomes of lung transplant recipients. Methods We conducted a retrospective, cohort study using the TriNetX Global Collaborative Network, which aggregates de-identified electronic health records from >160 healthcare organizations across North America, Europe, and Asia. Adult lung transplant recipients (≥18 years) between 2005 and 2024 were identified using ICD-10 and CPT codes. Patients with post-transplant fungal infection (aspergillosis, candidiasis, mucormycosis, histoplasmosis, coccidioidomycosis, blastomycosis) and matched controls without fungal infection within one year before or any time after transplant were identified. The index date was the date of transplantation. Propensity-score matching was performed on demographics, comorbidities, laboratory values, procedures and immunosuppressive medications. Outcomes included all-cause mortality (primary), allograft rejection, and chronic lung allograft dysfunction (CLAD) at 6 months, 1 year, 3 years, and 5 years. Kaplan-Meier and Cox proportional hazards models were used to estimate risk ratios (RRs), hazard ratios (HRs), and 95% confidence intervals (CIs). Analyses were conducted in TriNetX Analytics (v25.0, Cambridge, MA). Results A total of 3,083 patients with post-transplant fungal infection and 11,625 patients without infection were identified. Mean age was 58 ± 13 years, and 56% were male. The most common pulmonary comorbidities were chronic obstructive pulmonary disease, unspecified pulmonary fibrosis, idiopathic pulmonary fibrosis and bronchiectasis. Immunosuppression exposure was similar across groups. After propensity score matching across 56 clinical variables, both groups (1,790 per group) were well balanced. Mortality was higher in the fungal infection cohort at all follow-up points: 13.% vs 9% at 6 months (RR 1.45, 95% CI 1.2-1.75, p = 0.001), 17.8% vs 13% at 1 year (RR 1.36, p = 0.0001), 27.7% vs 21% at 3 years (RR 1.28, p < 0.0001), and 33 % vs 25% at 5 years (RR 1.32, p < 0.0001). Allograft rejection remained consistently higher (46-61% vs 22-34%), while CLAD occurred two- to three-fold more frequently (1.8-5.7% vs 0.7-2%). Conclusion Post-transplant fungal infection is independently associated with significantly increased mortality, acute rejection, and CLAD following lung transplantation. These findings underscore the need for early fungal surveillance, optimized antifungal prophylaxis, and individualized immunosuppression strategies to improve long-term patient outcomes. This abstract is funded by: None
ABSTRACT NUMBER: ESOC2026A1239 REGIONALIZATION OF A LARGE RURAL UNITED STATES TELESTROKE NETWORK
Adcock, Amelia, Miller, Blake, Findley, Scott, Burkhardt, Lucas, Coevering, Russell Van, Mandel, Daniel, Adcock, Amelia , Findley, Scott , Mandel, Daniel

Mayo Clinic

European Stroke Journal | May 6, 2026 | Volume: 11 | Issue: Supplement_1 | Pages: i348-i348

10.1093/esj/aakag023.604 Get It

Abstract Background and aims Interfacility transfers in rural areas are challenging due to limited ambulance and bed availability, image sharing issues, and access disparities. Regional transfers to strategically located primary stroke centers can reduce time to care, decrease helicopter use, support local economies, and conserve comprehensive stroke center (CSC) resources. This study established a primary stroke center as a regional transfer center (rSTC) within a telestroke network. Methods Over one year, stakeholders created regionally appropriate transfer workflows defined as patients without large vessel occlusion, low likelihood for neurosurgical decompression or critical illness within a rSTC and 4 surrounding centers. Continuous education and prospective case logs were maintained by the rSTC stroke coordinator and a retrospective chart review was conducted one year following the intervention period. Results Of 99 patients requiring transfer, 73 (73.7%) went to the rSTC, with an average stay of 2.1 days, no deaths, and no secondary CSC transfers. The remaining 26 (26.3%) were sent to the CSC, with longer stays (10.6 days) and higher mortality (23.1%). Transfers to the rSTC were faster (60 min vs. 188 min). Financial analysis showed significant EMS savings ($455,111) and local health system benefits ($730,000) when compared to the pre-intervention period. Conclusions Establishing an effective regional transfer model is possible with broad stakeholder engagement and regular network maintenance. rSTCs provide the right level of care for the right patient, improving efficient allocation of healthcare resources and avoiding futile transfers with costly admissions far from home while opening beds and reducing transfer times to CSCs. Conflict of interest Nothing to disclose
Abstract WP208: Strategic Regionalization of Stroke Transfers: Enhancing Patient-Centered Care Through Telestroke Networks
Miller, Blake, Petrone, Ashley , Findley, Scott , Mandel, Daniel M, Burkhardt, Lucas, Coevering, Russell J. Van , Adcock, Amelia

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.wp208 Get It

Background: Interfacility transfers, especially in rural settings, present challenges including limited ambulance availability, bed capacity, image sharing and disparities in access. Regional transfer minimizes time to definitive stroke center care, relies less on costly helicopter transport, supports local healthcare economies, and preserves comprehensive stroke center (CSC) resources for those most likely to benefit. Although these advantages are well-established and reflected in the guidelines, transfers within our connected care rural network were not previously accepted at hospitals outside of our central comprehensive stroke center (CSC). Methods: We identified a local primary stroke center to serve as the regional stroke transfer center (rSTC) within our larger telestroke network. Over one year, (2023-2024), stakeholder meetings with representatives from the rSTC, surrounding smaller hospitals and the CSC were conducted to pinpoint potential roadblocks and create workflows that facilitated regional transfer. Regionally appropriate transfers were defined as patients without LVO, low likelihood for any neurosurgical decompression, or critical illness requiring dedicated neuro-intensive care. Education surrounding these criteria occurred quarterly and case logs were maintained and reviewed by the rSTC stroke coordinator. Retrospective chart review one year following the intervention period (2024-2025) was performed. Results: Of the 99 total transferred patients, 73 (73.7%) patients were transferred regionally. Their average LOS was 2.1 days, with 0% mortality rate and 0% requiring a secondary transfer to the CSC. 26 (26.3%) patients went to the CSC; LOS was 10.6 days and mortality 23.1%. Transfer times were shorter for rSTC patients (60 min vs 188 min). Six CSC patients met regional criteria (26.3% overtriage rate). Conclusion: Establishing an effective regional transfer model is possible with broad stakeholder engagement and regular network maintenance. Following our intervention, most eligible patients remained local and were treated appropriately. Although there was a significant reduction of the patients transferred to the CSC, the majority of CSC transfers were also appropriately triaged. This rSTC model facilitates the care of all stroke patients by providing the right level of care for the right patient, avoiding futile transfers with costly admissions far from home while opening beds and reducing transfer times to CSCs.
Association between central adiposity and cognitive domain function in recently postmenopausal women: an analysis from the KEEPS-Cog substudy of the Kronos Early Estrogen Preventive Study
James, Taryn T. , Simó, Carola Ferrer, Salazar, Hector , Hulle, Carol A. Van , Wyman, Mary F. , Fischer, Barbara L., Bouges, Shenikqua , Umucu, Emre , Cedars, Marcelle I. , Løbo, Rogerio A. , Neal-Perry, Genevieve, Harman, S. Mitchell , Miller, Virginia M. , Gleason, Carey E. , Dowling, N. Maritza , Simó, Carola A. Ferrer, Ennis, Gilda E. , Johnson, Adrienne L. , McLester‐Davis, Lauren W. Y. , Gooding, Diane Carol , Kara, Firat , Kling, Juliana M. , Manson, JoAnn E. , Brinton, Eliot A. , Santoro, Nanette F. , Naftolin, Frederick , Pal, Lubna , Kantarci, Kejal

Mayo Clinic

Menopause | November 4, 2025 | Volume: 33 | Issue: 2 | Pages: 151-160

10.1097/gme.0000000000002666 | PMID 41186575 Get It

Objective: To determine associations between central adiposity, cognitive function, and randomized menopausal hormone therapy (MHT) in a reanalysis of the Kronos Early Estrogen Prevention Study-Cognitive and Affective (KEEPS-Cog) sub-study participants. Methods: KEEPS randomized 727 women (ages 42-58) who were <36 months postnatural menopause to oral conjugated equine estrogens (o-CEE), transdermal 17-β-estradiol (t-E2), or placebo for 48 months. Participants with diabetes, body mass index >35 kg/m 2 , coronary artery calcium score >50 Agatston Units, and other cardiometabolic disease risk indicators were excluded from enrollment. In the ancillary KEEPS-Cog study, cognitive tests were completed at baseline, 18-, 36-, and 48-month post-randomization. In these analyses, cognitive variables were summarized as four cognitive domain-specific factor scores: verbal learning and memory, auditory attention and working memory, visual attention and executive function, and speeded language and mental flexibility. Waist-hip-ratio (WHR), an indicator of central adiposity, was measured at screening (baseline) and modeled as a covariate in linear latent growth models assessing associations of MHT with cognitive functions at baseline and over time. Results: Higher baseline WHR was associated with poorer performance on all domain-specific cognitive outcomes at baseline and with changes in visual attention and executive function across time. Models including interaction effects were not significant for either o-CEE x WHR or t-E2 x WHR. Conclusion: Central adiposity is a risk factor for domain-specific cognitive decline, and thus, cognitive health effects should be investigated in early postmenopausal women, even in women with low cardiovascular risk statuses.
Staying Safe for the Long Haul: A Health Belief Model Analysis of COVID-19 Preventive Behaviors Through the Lens of Long COVID
Guidry, Jeanine P. D. , Burton, Candace W. , Perrin, Paul B. , Pinto, Melissa D. , Chelimsky, Thomas , Gharbo, Raouf, Carlyle, Kellie E. , Burton, Candace W , Pinto, Melissa D , Laestadius, Linnea Irina , Miller, Carrie A. , Stevens, Michael , Cuddeback, Gary S.

Mayo Clinic

Clinical Nursing Research | August 6, 2025 | Volume: 34 | Issue: 6 | Pages: 267-276

10.1177/10547738251360170 | PMID 40764982 Get It

Health problems associated with post-acute COVID-19, also known as “Long COVID,” range from mild to severe. The best defense against this potentially serious condition is to prevent COVID-19 infection and reinfection. The same preventive measures for COVID-19 may be used to help prevent the spread of Long COVID. This study used the Health Belief Model (HBM) to examine whether and how public understanding and awareness of Long COVID and its prevention shape the adoption of COVID-19 preventive behaviors. N = 605 English-speaking U.S.-based adults were recruited via Qualtrics. Predictors of intention to carry out COVID-19 preventive behaviors were investigated. Outcomes included behaviors relevant to preventing both acute and Long COVID. Across all models, except the one examining intent to get a vaccine booster, Black respondents were more likely than White respondents to express intent to carry out COVID-19 preventive behaviors. In addition, HBM constructs added significantly to the regression models. Susceptibility to Long COVID was significant for all behavioral outcomes (all p s < .05), self-efficacy for wearing a mask ( p < .001), and self-efficacy for testing for COVID-19 after exposure and before a social event ( p s < .001). In addition, perceived benefits for Long COVID prevention predicted intent of mask-wearing ( p < .001), testing before a social event ( p = .002), and getting a vaccine booster ( p = .001). Perceived severity of Long COVID did not significantly predict adherence to preventive behaviors. U.S. adults are more likely to express intent to carry out COVID-19 preventive behaviors, such as masking and receiving booster vaccines, when they report feeling greater susceptibility to Long COVID as well as greater self-efficacy for engaging in these preventive behaviors. Public health messaging about Long COVID with incorporation of HBM constructs may be an effective means of increasing continued recommended COVID-19 preventive behaviors, which also hold co-benefits for prevention of infections, such as influenza and measles, as well as emerging viruses such as avian flu.
Long-term effects of 4 years of menopausal hormone therapy on white matter integrity
Faubion, Laura L. , Tosakulwong, Nirobul, Lesnick, Timothy G. , Fought, Angela J. , Kendall‐Thomas, June, Kapoor, Ekta , Fields, Julie A. , Bailey, Kent R. , James, Taryn T. , Løbo, Rogerio A. , Pal, Lubna , Hammers, Dustin B. , Cedars, Marcelle I. , Miller, Virginia M. , Harman, S. Mitchell , Gleason, Carey E. , Kantarci, Kejal , Kantarci, Kejal , Mak, Elijah , Kara, Firat , Tosakulwong, Nirobul, Reid, Robert I. , Schwarz, Christopher G. , Manson, JoAnn E. , Hammers, Dustin B , Brinton, Eliot A. , Malek‐Ahmadi, Michael , Naftolin, Frederick , Santoro, Nanette F. , Dowling, N. Maritza

Mayo Clinic

Menopause | July 22, 2025 | Volume: 32 | Issue: 9 | Pages: 818-828

10.1097/gme.0000000000002562 | PMID 40694740 Get It

Objectives: To assess the long-term effects of 4 years of menopausal hormone therapy (mHT) on the brain’s white matter architecture in women who initiated mHT within 3 years of menopause onset. Methods: The Kronos Early Estrogen Prevention Study (KEEPS) was a multicenter, double-blind, randomized, placebo-controlled 4-year mHT trial with treatment arms of oral conjugated equine estrogens (oCEE), transdermal 17β-estradiol (tE2), and placebo in recently postmenopausal women. KEEPS Continuation was an observational follow-up of KEEPS participants. White matter integrity was evaluated in KEEPS Continuation participants 10 years after KEEPS completion using white matter hyperintensity volume, diffusion magnetic resonance imaging (dMRI) techniques, and cerebral infarcts. Linear regression models were fitted for each brain region to evaluate if there were differences in white matter between KEEPS treatment arms. Results: There was no evidence to suggest the long-term effects of 4 years of mHT on brain white matter in KEEPS Continuation participants [n=266, mean age 67 (58-73)]. No differences in dMRI metrics were found in each of the treatment arms (oCEE n=70; tE2 n=79) when compared to placebo (n=94), following a false discovery rate adjustment for multiple comparisons. There were no statistically significant differences in white matter hyperintensity volume or infarct occurrence when comparing each of the treatment arms to placebo. Conclusions: We found no evidence of the long-term effect of 4-year mHT on white matter integrity when compared to placebo, consistent with emerging evidence of the safety of short-term use of mHT in recently postmenopausal women.
Acute exogenous oestradiol augments endothelial and smooth muscle vasodilatory responsiveness in premenopausal but not postmenopausal females
Dillon, Gabrielle A. , Limberg, Jacqueline K. , Nicholson, Wayne T. , Joyner, Michael J. , Baker, Sarah E. , Miller, Virginia M. , Ranadive, Sushant M. , Harvey, Ronée E , Limberg, Jacqueline K , Nicholson, Wayne T , Joyner, Michael J , Baker, Sarah E , Harvey, Ronée E.

Mayo Clinic

The Journal of Physiology | March 11, 2025 | Volume: 603 | Issue: 8 | Pages: 2301-2311

10.1113/jp287719 | PMID 40012199 Get It

AbstractMenopause is associated with vascular dysfunction. During the menopausal transition, endogenous oestradiol concentrations diminish. Oestradiol is vasoprotective because it has direct and indirect effects on the vasculature. The present study aimed to determine the effect of acute exogenous oestradiol on endothelium‐dependent, endothelium independent and β2‐adrenergic receptor‐induced vasodilatation in females. Forearm blood flow (venous occlusion plethysmography) was measured during brachial intraarterial infusions of ACh (endothelium‐dependent agonist), sodium nitroprusside (endothelium independent agonist) and terbutaline (β2‐adrenergic receptor agonist) with and without concurrent infusion of 17β‐oestradiol. Nine young premenopausal (age: 26 ± 4 years) and nine postmenopausal (PM, age: 58 ± 4 years, 8 ± 1 years post‐menopause) females completed the study. Concurrent oestradiol infusion augmented the vasodilatory response to ACh, sodium nitroprusside and terbutaline in young premenopausal (all P < 0.05) but not older postmenopausal (all P > 0.05), females. Local infusion of exogenous 17β‐oestradiol augmented endothelial and smooth muscle microvascular vasodilatation in premenopausal but not postmenopausal, females. imageKey points Menopause is associated with vascular dysfunction. Because oestradiol has vasoprotective effects, the menopause‐associated drop in oestradiol concentrations is hypothesized to contribute to vascular dysfunction during the menopause transition. The present study shows that local infusion of exogenous oestradiol augmented microvascular vasodilatation in premenopausal but not postmenopausal females.
Associations of blood pressure with white matter hyperintensities later in life; influence of short-term menopausal hormone therapy
Kara, Firat , Tosakulwong, Nirubol , Lesnick, Timothy G. , Fought, Angela J. , Kendell-Thomas, June, Kapoor, Ekta , Faubion, Laura L. , Fields, Julie A. , Min, Hoon‐Ki , Lowe, Val J. , Jack, Clifford R. , Bailey, Kent R. , James, Taryn T. , Løbo, Rogerio A. , Pal, Lubna, Hammers, Dustin B. , Cedars, Marcelle I. , Miller, Virginia M. , Harman, S. Mitchell , Gleason, Carey E. , Kantarci, Kejal , Pal, Lubna , Kantarci, Kejal , Min, Hoon-Ki Paul , Jack, Clifford R , Kara, Firat , Kapoor, Ekta , Schwarz, Christopher G. , Senjem, Matthew L. , Manson, JoAnn E. , Hammers, Dustin B , Malek‐Ahmadi, Michael , Naftolin, Frederick , Santoro, Nanette F. , Dowling, N. Maritza

Mayo Clinic

Menopause | December 27, 2024 | Volume: 32 | Issue: 1 | Pages: 12-22

10.1097/gme.0000000000002481 | PMID 39729067 Get It

Abstract Objective To assess the association of systolic and diastolic blood pressure (SBP and DBP) in recently menopausal women with white matter hyperintensity (WMH) volume later in life and determine whether short-term menopausal hormone therapy (mHT) modifies these associations. Methods Kronos Early Estrogen Prevention Study (KEEPS) was a multicenter, randomized, double-blinded, placebo-controlled 4-year mHT trial (oral conjugated equine estrogens or transdermal 17β-estradiol). KEEPS continuation was an observational follow-up of the participants 10 years after the end of mHT. The associations between KEEPS baseline blood pressure (BP) with KEEPS continuation WMH volume were examined adjusting for covariates in model 1 (age, total intracranial volume, study site, mHT type) and model 2 (additionally conventional CVD risk factors). Interaction terms (BP × mHT type) were added into the linear regression models. Results The mean ± SD ages of participants were 53 (±2) years at KEEPS baseline and 67 (±2) years at KEEPS continuation. Elevated BP at KEEPS baseline was associated with greater WMH volume measured 14 years later (model 1: SBP: β = 0.01 [95% CI, 0.001‐0.01] and DBP: β = 0.01 [95% CI, 0.003‐0.03]) and after additionally adjusting for CVD risk factors (model 2). We did not find any evidence that mHT versus placebo modified these associations. Topographically, higher BP was associated with greater periventricular WMH in the frontal and parietal lobes. Conclusion Our findings suggest the importance of maintaining normal BP in recently postmenopausal women with low CVD risk, irrespective of short-term mHT usage, to potentially reduce the risk of WMH later in life.
Experimental Evaluation of Bleeding Complications, Thrombogenicity and Neointimal Characteristics of Prosthetic Patch Materials Used for Carotid Angioplasty
Rhee, Robert Y. , Gloviczki, Péter , Cambria, Robert A., Miller, Virginia M. , Gloviczki, Péter

Mayo Clinic

Cardiovascular Surgery | September 24, 2024 | Volume: 4 | Issue: 6 | Pages: 746-752

10.1177/096721099600400612 | PMID 9013003 Get It

Experiments were designed to compare perioperative blood loss, early thrombogenicity and morphologic and functional characteristics of the neointima of three types of prosthetic materials used for carotid artery patch angioplasty. Bilateral carotid patch angioplasties were performed in 20 dogs, using 20 gelatin-impregnated fluoropassivated Dacron (GIF), 10 untreated knitted Dacron and 10 expanded polytetrafluoroethylene (PTFE) patches (5 cm2). Intraoperative blood loss, platelet deposition at 24 h and neointimal morphology at 6 weeks after the operation were assessed. Bioassay of the neointima was performed at 6 weeks in 16 patches. Mean (s.e.m.) blood loss was significantly less in GIF patches (14.7 (2.7) ml) compared with either PTFE (75.6 (24) ml) or untreated Dacron (64. 3 (9.5)) ( P < 0.005). Mean (s.e.m.) platelet deposition in GIF patches (1380 (328) platelets/cm2) was approximately 50% less at 24 h than in untreated Dacron (2562 (1035) platelets/cm2) or PTFE (2140 (998) platelets/cm2) patches ( P < 0.05). Neointimal coverage was greater in PTFE (94 (1.3%)) compared with GIF (79 (2.7%)) or untreated Dacron (86(2.4%)) patches ( P < 0.05). The thickness of the neointimal layer of PTFE (0.5 (0.01) mm) patches was greater than other patch types; GIF (0.2 (0.01) mm) or untreated Dacron (0.3 (0.01) mm) ( P < 0.05). Under bioassay conditions, acetylcholine caused release of vasoactive relaxing factor(s) from all patches. However, relaxations from baseline were less with GIF patches (−37.9 (11.7)% versus −54.5 (9.6) for untreated Dacron; −50.2 (15.2)% for PTFE) ( P = n.s.). Endothelin-1 release occurred from all patches and was increased with the extent of neointimal coverage. These data demonstrate that GIF patches caused the least perioperative bleeding, were the least thrombogenic at 24 h and developed the thinnest neointima at 6 weeks. All patch materials developed a functioning neointima.